S&P 500   5,117.21 (+0.41%)
DOW   39,045.84 (+0.13%)
QQQ   442.51 (+0.80%)
AAPL   178.21 (-1.41%)
MSFT   412.02 (-0.39%)
META   499.15 (+1.84%)
GOOGL   137.45 (-0.73%)
AMZN   177.67 (+0.51%)
TSLA   199.55 (-1.15%)
NVDA   814.11 (+2.91%)
NIO   5.79 (+0.70%)
AMD   197.65 (+2.66%)
BABA   74.81 (+1.05%)
T   17.00 (+0.41%)
F   12.49 (+0.40%)
MU   95.67 (+5.58%)
CGC   3.27 (-0.61%)
GE   158.49 (+1.02%)
DIS   111.37 (-0.19%)
AMC   4.45 (+3.01%)
PFE   26.62 (+0.23%)
PYPL   61.24 (+1.49%)
XOM   106.01 (+1.43%)
S&P 500   5,117.21 (+0.41%)
DOW   39,045.84 (+0.13%)
QQQ   442.51 (+0.80%)
AAPL   178.21 (-1.41%)
MSFT   412.02 (-0.39%)
META   499.15 (+1.84%)
GOOGL   137.45 (-0.73%)
AMZN   177.67 (+0.51%)
TSLA   199.55 (-1.15%)
NVDA   814.11 (+2.91%)
NIO   5.79 (+0.70%)
AMD   197.65 (+2.66%)
BABA   74.81 (+1.05%)
T   17.00 (+0.41%)
F   12.49 (+0.40%)
MU   95.67 (+5.58%)
CGC   3.27 (-0.61%)
GE   158.49 (+1.02%)
DIS   111.37 (-0.19%)
AMC   4.45 (+3.01%)
PFE   26.62 (+0.23%)
PYPL   61.24 (+1.49%)
XOM   106.01 (+1.43%)
S&P 500   5,117.21 (+0.41%)
DOW   39,045.84 (+0.13%)
QQQ   442.51 (+0.80%)
AAPL   178.21 (-1.41%)
MSFT   412.02 (-0.39%)
META   499.15 (+1.84%)
GOOGL   137.45 (-0.73%)
AMZN   177.67 (+0.51%)
TSLA   199.55 (-1.15%)
NVDA   814.11 (+2.91%)
NIO   5.79 (+0.70%)
AMD   197.65 (+2.66%)
BABA   74.81 (+1.05%)
T   17.00 (+0.41%)
F   12.49 (+0.40%)
MU   95.67 (+5.58%)
CGC   3.27 (-0.61%)
GE   158.49 (+1.02%)
DIS   111.37 (-0.19%)
AMC   4.45 (+3.01%)
PFE   26.62 (+0.23%)
PYPL   61.24 (+1.49%)
XOM   106.01 (+1.43%)
S&P 500   5,117.21 (+0.41%)
DOW   39,045.84 (+0.13%)
QQQ   442.51 (+0.80%)
AAPL   178.21 (-1.41%)
MSFT   412.02 (-0.39%)
META   499.15 (+1.84%)
GOOGL   137.45 (-0.73%)
AMZN   177.67 (+0.51%)
TSLA   199.55 (-1.15%)
NVDA   814.11 (+2.91%)
NIO   5.79 (+0.70%)
AMD   197.65 (+2.66%)
BABA   74.81 (+1.05%)
T   17.00 (+0.41%)
F   12.49 (+0.40%)
MU   95.67 (+5.58%)
CGC   3.27 (-0.61%)
GE   158.49 (+1.02%)
DIS   111.37 (-0.19%)
AMC   4.45 (+3.01%)
PFE   26.62 (+0.23%)
PYPL   61.24 (+1.49%)
XOM   106.01 (+1.43%)
NASDAQ:CRTX

Cortexyme (CRTX) Stock Price, News & Analysis

$1.30
-0.04 (-2.99%)
(As of 02/29/2024 ET)
Today's Range
$1.30
$1.37
50-Day Range
$1.05
$1.40
52-Week Range
$1.78
$40.66
Volume
57,121 shs
Average Volume
620,672 shs
Market Capitalization
$39.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CRTX stock logo

About Cortexyme Stock (NASDAQ:CRTX)

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

CRTX Stock Price History

CRTX Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
See More Headlines
Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2021
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:CRTX
CUSIP
21924P10
Fax
N/A
Employees
55
Year Founded
2012

Profitability

Net Income
$-89,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
21,739,000
Market Cap
$39.20 million
Optionable
Not Optionable
Beta
1.40

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Leslie J. Holsinger Ph.D. (Age 57)
    Exec. VP of R&D
    Comp: $603.85k
  • Dr. Dirk Thye M.D. (Age 52)
    CEO & Director
  • Mr. Ted Monohon (Age 56)
    VP of Fin., Principal Financial Officer & Chief Accounting Officer
  • Mr. Brendan Hannah M.B.A.
    Chief Bus. Officer
  • Dr. Karen L. Smith L.L.M (Age 54)
    L.L.M., M.B.A., M.D., PH.D., Chief Medical Officer














CRTX Stock Analysis - Frequently Asked Questions

How have CRTX shares performed in 2024?

Cortexyme's stock was trading at $1.05 on January 1st, 2024. Since then, CRTX stock has increased by 23.8% and is now trading at $1.30.
View the best growth stocks for 2024 here
.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) released its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.05.

What other stocks do shareholders of Cortexyme own?
When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRTX) was last updated on 3/1/2024 by MarketBeat.com Staff